Therapeutic Effect of EDTA in Experimental Model of Multiple Sclerosis

References

• Peiris M, Monteith GR, Roberts-Thomson SJ, Cabot PJ. A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies. J Neurosci Methods 2007 Jul 30;163(2):245–54.
   PubMedGoogle Scholar
• Furlan R, Kurne A, Bergami A, Brambilla E, Maucci R, Gasparini L, et al. A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol 2004 May;150(1–2):10–9.
   PubMedGoogle Scholar
• Zaheer S, Wu Y, Bassett J, Yang B, Zaheer A. Glia maturation factor regulation of STAT expression: a novel mechanism in experimental autoimmune encephalomyelitis. Neurochem Res 2007 Dec;32(12):2123–31.
   PubMedGoogle Scholar
• Wang Y, Kai H, Chang F, Shibata K, Tahara-Hanaoka S, Honda S, et al. A critical role of LFA-1 in the development of Th17 cells and induction of experimental autoimmune encephalomyelytis. Biochem Biophys Res Commun 2007 Feb 23;353(4):857–62.
   PubMedGoogle Scholar
• Xiao BG, Ma CG, Xu LY, Link H, Lu CZ. IL-12/IFN-gamma/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. Mol Immunol 2008 Feb;45(4):1191–6.
   PubMedGoogle Scholar
• Jiang HR, Al Rasebi Z, Mensah-Brown E, Shahin A, Xu D, Goodyear CS, et al. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol 2009 Jan 15;182(2):1167–73.
   PubMedGoogle Scholar
• Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurological Sciences 2007 Aug 15;259(1–2):79–84.
   PubMedGoogle Scholar
• Fisher AE, Maxwell SC, Naughton DP. Superoxide and hydrogen peroxide suppression by metal ions and their EDTA complexes. Biochem Biophys Res Commun 2004 Mar 26;316(1):48–51.
   PubMedGoogle Scholar
• Lanigan RS, Yamarik TA. Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA. Int J Toxicol 2002;21 Suppl 2:95–142.
   PubMedGoogle Scholar
• Ernst E. Chelation therapy for coronary heart disease: an overview of all clinical investigations. Am Heart J 2000 Jul;140(1):139–41.
   PubMed Web of Science ®Google Scholar
• Lewin MR. Chelation therapy for cardiovascular disease. Review and commentary. Tex Heart Inst J 1997;24(2):81–9.
   PubMedGoogle Scholar
• Seely DM, Wu P, Mills EJ. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovasc Disord 2005;5:32.
   PubMedGoogle Scholar
• Cory-Slechta DA, Weiss B. Efficacy of the chelating agent CaEDTA in reversing lead-induced changes in behavior. Neurotoxicology 1989 Winter;10(4):685–97.
   PubMedGoogle Scholar
• Meldrum JB, Ko KW. Effects of calcium disodium EDTA and meso-2,3-dimercaptosuccinic acid on tissue concentrations of lead for use in treatment of calves with experimentally induced lead toxicosis. Am J Vet Res 2003 Jun;64(6):672–6.
   PubMedGoogle Scholar
• Skundric DS, Zakarian V, Dai R, Lisak RP, Tse HY, James J. Distinct immune regulation of the response to H-2b restricted epitope of MOG causes relapsing-remitting EAE in H-2b/s mice. J Neuroimmunol 2003 Mar;136(1–2):34–45.
   PubMedGoogle Scholar
• Natarajan C, Muthian G, Barak Y, Evans RM, Bright JJ. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J Immunol 2003 Dec 1;171(11):5743–50.
   PubMedGoogle Scholar
• Nencini C, Cavallo F, Capasso A, Franchi GG, Giorgio G, Micheli L. Evaluation of antioxidative properties of Allium species growing wild in Italy. Phytother Res 2007 Sep;21(9):874–8.
   PubMedGoogle Scholar
• Phizackerley PJ, Al-Dabbagh SA. The estimation of nitrate and nitrite in saliva and urine. Anal Biochem 1983 May;131(1):242–5.
   PubMedGoogle Scholar
• Kayhan B, Aharoni R, Arnon R. Glatiramer acetate (Copaxone) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis. ImmunolLetts 2003 Sep 8;88(3):185–92.
   Google Scholar
• Tuohy VK, Lu Z, Sobel RA, Laursen RA, Lees MB. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol 1989 Mar 1;142(5):1523–7.
   PubMedGoogle Scholar
• Mendel I, Kerlero DR, Ben Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995;25:1951–9.
   PubMed Web of Science ®Google Scholar
• McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 1992 Jun;38(3):229–40.
   PubMedGoogle Scholar
• Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurologica Scand 1988 Oct;78(4):318–23.
   PubMedGoogle Scholar
• Miller A, al-Sabbagh A, Santos LM, Das MP, Weiner HL. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J Immunol 1993 Dec 15;151(12):7307–15.
   PubMedGoogle Scholar
• Sakakura Y, Hosokawa Y, Tsuruga E, Irie K, Yajima T. In situ localization of gelatinolytic activity during development and resorption of Meckel’s cartilage in mice. Eur J Oral Sciences 2007 Jun;115(3):212–23.
   PubMedGoogle Scholar
• Foglieni C, Fulgenzi A, Ticozzi P, Pellegatta F, Sciorati C, Belloni D, et al. Protective effect of EDTA preadministration on renal ischemia. BMC Nephrol 2006;7:5.
   PubMedGoogle Scholar
• Hininger I, Waters R, Osman M, Garrel C, Fernholz K, Roussel AM, et al. Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy. Free Radical Biol Med 2005 Jun 15;38(12):1565–70.
   PubMed Web of Science ®Google Scholar
• Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994 Aug 26;265(5176):1237–40.
   PubMed Web of Science ®Google Scholar
• Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exper Med 1994 Nov 1;180(5):1961–6.
   PubMedGoogle Scholar
• Allione A, Bernabei P, Bosticardo M, Ariotti S, Forni G, Novelli F. Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. J Immunol 1999 Oct 15;163(8):4182–91.
   PubMedGoogle Scholar
• Dietlin TA, Hofman FM, Gilmore W, Stohlman SA, van der Veen RC. T cell expansion is regulated by activated Gr-1+ splenocytes. Cellular Immunol 2005 May;235(1):39–45.
   PubMedGoogle Scholar
• Staykova MA, Berven LA, Cowden WB, Willenborg DO, Crouch MF. Nitric oxide induces polarization of actin in encephalitogenic T cells and inhibits their in vitro trans-endothelial migration in a p70S6 kinase-independent manner. FASEB J 2003 Jul;17(10):1337–9.
   PubMedGoogle Scholar
• Sun Y, Liu J, Qian F, Xu Q. Nitric oxide inhibits T cell adhesion and migration by down-regulation of beta1-integrin expression in immunologically liver-injured mice. Intern Immunopharmacol 2006 Apr;6(4):616–26.
   PubMedGoogle Scholar